Introducing Bupropion Tablets by PharmAlliance International Labs

Welcome to PharmAlliance International Labs, where we are dedicated to promoting the health and well-being of individuals worldwide. Our Bupropion Tablets represent a breakthrough solution for individuals grappling with mood disorders and seeking smoking cessation assistance. With an unwavering commitment to efficacy and safety, our product is poised to enhance the quality of life for those in need.

Drug Classification:

Bupropion falls within the class of medications known as aminoketones and is categorized as an atypical antidepressant. Distinguished by its unique pharmacological profile, Bupropion exhibits dual inhibition of dopamine and norepinephrine reuptake, rendering it effective in managing depression and aiding smoking cessation efforts by curbing nicotine cravings and withdrawal symptoms.

Formulations:

Bupropion Tablets:

• Strength: Each tablet contains 150mg of Bupropion.
• Product Form: Oral tablets for convenient administration.
• Packing Specifications: Available in packs of 20 tablets.

Indications:

Bupropion Tablets are indicated for the treatment of:

Major Depressive Disorder (MDD): Effective in alleviating symptoms of depression, including persistent sadness, loss of interest or pleasure in activities, changes in appetite or weight, and disturbances in sleep or activity.

Smoking Cessation: Facilitates smoking cessation by reducing the urge to smoke and minimizing withdrawal symptoms associated with nicotine dependence.

Usage:

Administer Bupropion Tablets orally as directed by a healthcare professional. For depression treatment, the recommended starting dose is typically 150 mg once daily, with adjustments made based on individual response and tolerance. When utilized for smoking cessation, the initial dose is generally 150 mg once daily for the first 3 days, followed by an increase to 150 mg twice daily thereafter.

Dosage:

Dosage adjustments may be necessary depending on the indication being treated and individual patient response. It is imperative to adhere to the prescribed dosage regimen and avoid abrupt discontinuation to mitigate the risk of withdrawal symptoms or depression recurrence.

Pharmacokinetics:

Following oral administration, Bupropion is readily absorbed, with peak plasma concentrations attained within 2 to 3 hours. Extensive hepatic metabolism occurs, predominantly via the cytochrome P450 enzyme system, yielding active metabolites such as hydroxybupropion. The elimination half-life of Bupropion and its metabolites is approximately 21 hours, facilitating convenient once or twice-daily dosing.

Pharmacodynamics:

Bupropion exerts its antidepressant and smoking cessation effects through the inhibition of dopamine and norepinephrine reuptake in the brain. By augmenting neurotransmitter levels within synaptic clefts, Bupropion regulates mood and diminishes cravings associated with nicotine dependence.

Side Effects:

Common side effects of Bupropion may encompass dry mouth, headache, nausea, insomnia, and agitation. Less frequently observed adverse reactions may include constipation, dizziness, tremor, and weight loss. While rare, Bupropion may be associated with more serious adverse events such as seizures, serotonin syndrome, or allergic reactions.

Place your trust in the efficacy and safety of Bupropion Tablets from PharmAlliance International Labs. Whether you seek relief from depression or assistance with smoking cessation, our product stands as a dependable solution to help you attain your health objectives. For further information, please visit our website or consult your healthcare provider.